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A left ventricular assist device is a mechanical pump implanted in patients with
heart failure that continuously takes blood from the left ventricle and delivers it to the
aorta, thus decreasing ventricular load. The device is typically considered as a ‘bridge to
transplant’, i.e. as a temporary therapy, and involves several risks. Modified ventricular
hemodynamics due to a heart pump implantation is studied in-vitro using an elastic
ventricle. The ventricle is incorporated into a pulse duplicator setup, which prescribes
realistic pulsatile inflow/outflow to mimic a weak ejection fraction. A continuous axial
pump mimics a ventricular assist device and its effect on the ventricular hemodynamics is
investigated as a function of the pump flow suction. Using particle image velocimetry,
pump flow effectiveness at providing unloading on the ventricle and increasing ejection
is observed and understanding if proper recirculation of the myocardium down to the
apex is restored under varying flow rate
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CHAPTER I
INTRODUCTION
1.1 Heart Physiology
The heart, one of the most crucial organs in the body, functions as a powerful
pump. The major role of this pump is supplying oxygenated blood to the body while
simultaneously transporting de-oxygenated blood to the respiratory system to be
replenished with oxygen. The heart is made up of four chambers two atria and two
ventricles, one for both the right and left heart, separated by four heart valves. The right
side of the heart, shown in blue in Figure 1(a), transports deoxygenated blood from the
right heart to the lungs via the pulmonary circuit for oxygenation before entering the left
heart. The left side of the heart, outlined in red in Figure 1(a), carries oxygenated blood
by means of the systemic circuit from the left heart to the rest of the body minus the
lungs.
Veins transport blood to the atria before it flows in to the ventricles which are
responsible for pumping it through the circulatory system. Deoxygenated blood enters
the right atrium and passes to the right ventricle through the tricuspid valve. From the
ventricle blood is passed to the lungs, to be oxygenated, through the pulmonary valve and
arteries. Oxygenated blood returns to the left heart from the lungs through the left atrium
before it is pumped into the left ventricle (LV). The oxygenated blood enters the LV
through the mitral valve where it is then pumped to the rest of the body via the aorta. The
1

LV is the driving force behind systemic circulation and the focus of this hemodynamic
study. The left heart has to withstand the largest pressure differences in the range 1.6–2.1
x 104 Pa (120–160 mmHg) between atrium and ventricle in a healthy adult. The
myocardium of the left ventricle is thick, as seen in Figure 1(b), since it is subject to high
pressures and responsible for pumping blood through the systemic circuit.

Figure 1

(a) Diagram of the anatomy and blood flow of the heart. From
(texasheart.org) (b)Anatomical cross-section of the heart, showing the inside
of all four chambers and the myocardium. From (Henry Vandyke Carter)
1.2 Cardiac Cycle

Unidirectional flow in the heart is achieved by the four heart valves. The valves
can be classified as either atrioventricular or semilunar. The atrioventricular valves,
named for their position between atria and ventricles, are the mitral value (MV) and
2

tricuspid valve (TV). The semilunar valves composed of three half-moon shaped cusps
consist of the aortic valve (AV) and pulmonary valve. During each cardiac cycle, the
blood flow and pressure occurring within the flow loop is outlined.
The cycle is divided into two phase, systole and diastole. In the left side of the
heart, systole starts at the beginning of isovolumic contraction, when LV pressure
exceeds atrial pressure, and the ventricles contract and blood is ejected. The mitral valve
closes at the crossover point of pressures between the ventricle and atria. It ends just
before relaxation. The LV ejects blood during systole while the AV is responsible for
preventing regurgitation of blood back into the ventricle during diastole. Diastole begins
when the ventricles are filled, and the atrioventricular valves are open allowing blood
flow from the atrium into the ventricles. Calcium ions are taken up into the sarcoplasmic
reticulum, myocyte relaxation dominates contraction, LV pressure falls, the ventricle
begins to relax and the aortic valve closes.
Looking at the diagram in Figure 2 of the pressure volume loop, the top bold
border is ventricular systole with diastole represented by non-bold border at the bottom.

3

Figure 2

LV pressure and volume changes during a single cardiac cycle

Filling begins at the bottom left corner point N, where LV pressure drops below
atrial pressure and the mitral valve opens. This point N also represents end systolic
volume (ESV) of the ventricle at about 70 ml. Initially, the filling phase is very rapid, but
slows as ventricular pressure rises to that of the atrium. Atrial contraction completes the
filling at point O where we get end diastolic volume (EDV) of 150 ml.
EDV – ESV = stroke volume (SV) which is about 80 ml. Cardiac Output (CO) =
Stroke Volume (SV) x Heart Rate (HR); CO = SV x HR (L/min) Under normal healthy
conditions, heart pumping volume is about 6-8 L/min, doubling or more during aerobic
exercise. EDV also represents ventricular volume in its entirety at the end of ventricular
diastole. SV/EDV gives us the normal ejection fraction of about 0.5.
.

From point O to point P, there is a rapid rise in ventricular pressure also known as

isovolumic contraction. The contracting ventricle’s pressure exceeds that of the atrium
4

causing the mitral valve to close, giving a constant volume of blood within the ventricle
for a brief period. At point P, ventricular pressure exceeds aortic pressure forcing the aortic
valve open through which blood is ejected. The walls of the aorta become distended, but
as it slows the pressure drops and the arterial walls recoil reversing the blood flow just
enough to close the aortic valve ending the ejection interval.
At the end of ejection, when the PV loop has reached the top left corner at point
M, all valves are closed, and the ventricle relaxes at constant volume (isovolumic
relaxation represented by the line M-N). Ventricular pressure drops rapidly, and once it
falls below that of the atrium, a new cycle begins, and the PV loop continues.
The inflow/outflow velocity during the ﬁrst part of the cardiac cycle has one
strong peak (E–wave) due to early diastolic filling and a secondary peak in late diastole
caused by atrial contraction (A–wave) as seen in Figure 3(a). Depicted in Figure 3(b) is
the time evolution of the LV volume, also considered the desired inflow/outflow curve.
This flow induces a passive variation of the total volume of the system which, due to
incompressibility, is copied by the ventricle. This inactive contraction and relaxation of
the ventricle imposes the upper surface of the inﬂow by the mitral channel according to a
pumping function which gives the velocity proﬁle.

5

Figure 3

(a) For a complete cardiac cycle, the time evolution of the inflow/outflow
velocity, U*(t), over a cardiac cycle. (b) The time evolution of the volume,
V*(t), of the left ventricle. Both plots are in dimensional units.

This function is composed of a ﬁrst inﬂow phase, diastole, where U(t) is positive
and the ﬂow is pumped in the ventricle and a second outﬂow phase, systole, in which U(t)
becomes negative and the ﬂuid exits the LV through the aortic channel.18
The LV volume evolution over time is determined and set in such a way that the
ﬂow rate resembles that of an ineﬃcient and failing left ventricle, which is generally
observed in the elderly or those suffering from cardiovascular disease, as well as in a LV
under normal healthy conditions.

1.3 Cardiovascular Disease and LV disfunction
Cardiovascular disease (CVD) is the leading cause of death, accounting for more
than 17.9 million deaths per year in 2015, a number predicted to grow to more than 23.6
million by the year 2030. CVD, as the underlying cause of death, accounts for nearly one
in three deaths in the US keeping it ranked the number one cause of death in the US.
6

Total medical costs of CVD are projected to increase to $749 billion in 2035 from an
estimated cost of $204.8 billion averaged annually in 2013-2014.2
Due to the high pressures the LV must be able to withstand, it is the most
vulnerable part of the heart to damage. The aortic and mitral valves, responsible for
directing blood to the aorta and from the atrium to the ventricle, exist in a physically
demanding mechanical environment. The LV is constantly under complex and larger
fluid dynamic forces. LV dynamics are a result of the interaction between the
myocardium’s active contraction/relaxation and the blood’s surface loads. The LV
experiences highly fluctuating pressure and fluid shear stress with damaging effects. LV
impairment can lead to cardiac pathologies and eventual heart failure. One of the most
common causes of heart failure is cardiomyopathy and while this condition often goes
undiagnosed, roughly 1 in 500 adults may have developed a form of cardiomyopathy.12
Cardiomyopathies are diseases of the heart muscle associated with cardiac
dysfunction and can be broken down into different subtypes. The way that the heart’s
shape, size, and thickness of the muscle walls is affected depends on the type of
cardiomyopathy. The most common subtype is dilated cardiomyopathy (DCM),
accounting for more than 90% of all cardiomyopathies. Defining elements of this disease
include left ventricular enlargement and decreased contractility.23 As the myocardium
becomes damaged, the ventricle’s muscle tissue becomes weakened and the LV is unable
to function on its own. This disease affects the structure of the heart, reducing its ability
to pump blood to the rest of the body.32
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Figure 4

Anatomy and function of a physiologically healthy heart and that of a heart
with DCM. From (akronchildrens.org)

DCM affects the structure of the heart which reduces its ability to pump blood to
the rest of the body. DCM often begins in the left ventricle, where the inside of the
chamber enlarges and the disease spreads from the heart’s main pumping chamber to the
right ventricle and on to the atria. The chambers of the heart dilate, causing abnormal
contraction of the myocardium as it weakens, and DCM can also cause formation of
blood clots and heart valve problems. Despite improvements made towards diagnostic
procedures and intervention methods to reduce the likelihood of mortality, it is predicted
that we will not see positive outcomes ahead. Cardiovascular disease is predicted to
show an increase in occurrence in the forthcoming years due to its correlation to risk
factors such as age, obesity, tobacco use, and diabetes. This coupled with projected
8

increases to already high cost treatments has further confirmed CVD as the leading cause
of mortality in developed countries.
Research of new investigative medical tools can help diagnose and possibly
reverse this unfavorable prospected reality of the incidence of heart failure. Development
of new technologies able to improve treatment outcomes would significantly improve the
projected tendency of cardio health. Improvements and continuous progress have been
seen already in computational engineering.18 Foremost, the medical community relies on
digital imaging techniques and computer aided procedures. There is an unprecedented
availability of multi-physics/multi-dimensional computational models on powerful
computers under realistic configurations with direct interest for clinical application.

1.4 Demand for Ventricular Assist Devices
When a patient experiences cardiac failure, the heart is too weak to efficiently
pump blood in or out. Therefore, the heart makes efforts to overcome its gradual
weakening. The heart expands attempting to hold more blood and maintain a balanced
amount that’s being pumped out. Most patients experience heart failure due to the failure
of the left ventricle, and as the failure progresses, the stress on the left ventricle becomes
so great that it cannot send enough blood to the other organs of the body. At this point, it
is only a matter of time before medicine and pacemakers are no longer able to assist in
the proper functioning of the heart, and a transplant or mechanical pump is needed.
Donor hearts are in short supply, and, with as many as 50,000 people each year needing a
transplant, many patients die each year waiting for a transplant. Due to this shortage,
researchers have developed mechanical pumps known as ventricular assist devices
9

(VADs) which take over some of the work of the heart. VADs help the ventricles pump
blood by easing the workload on these failing hearts (sometimes called “unloading”).
LVADs are implemented in patients experiencing some form of heart failure,
when their heart cannot pump enough blood necessary to circulate through their body.

Figure 5

Diagram of Jarvik LVAD implementation into a patient heart

Typically, this is due to DCM where the myocardium is not powerful enough to
properly eject blood from the LV, which can lead to myocardial infarction or failure of
the aortic valve due to stenosis. The Jarvik-2000, shown in Figure 5, is a non-pulsatile
axial-flow LVAD used in end-stage heart failure patients typically as a bridge to
transplant or permanently if the case of heart failure is untreatable. As mentioned earlier
when discussing the cardiac cycle, in healthy, normally functioning hearts, the pumping
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volume is about 6-8 L/min. The average output of a continuous flow heart pump like the
Jarvik is 5 L/min with a maximum of 7 L/min, which is within the physiological range.
Permanent destination therapy (DT) has become increasingly popular as of recent
years in this face of donor organ shortage and increasing numbers of elderly patients
ineligible for heart transplants. Advances in technology, particularly the emergence of
smaller and more durable continuous flow left ventricular assist devices (CF-LVADs),
have continued to improve long-term outcomes and living quality. As the average
duration of long-term support increases, device durability, measured by rate of device
failure over time, becomes an increasing contributor to patient survival, morbidity, and
quality of life. While in severe cases device failure can lead to fatal consequences, the
requirement for pump replacement in the event of failure comes with increasing
healthcare costs and exposure of the patient to potentially life-threatening complications
like thrombosis and bleeding. Overall, the durability of LVADs is dependent upon
several factors, such as implantation technique, pump settings, device design, and patient
complications like infection or bleeding.
LVADs support a severely depressed LV and pump blood to the rest of the body
by reducing LV pressure and volume overload that decreases LV wall stress. It is
important to understand myocardial wall stress on the ventricle because it has a
correlation to regional coronary blood flow, oxygen consumption, and molecular systems
associated with the development of cardiac insufficiency. CF-LVADs are typically
implanted in patients characterized with severe LV systolic dysfunction and reduced
ejection fraction (EF). According to experts, a normal EF in a healthy adult should be at
least 50%, preferably ≥55% and ranging up to 70%. An EF ≤50% is considered reduced,
11

with the range between 50 and 55 percent being considered preserved or borderline.9
Measurements falling below 40% may be evidence of heart failure or cardiomyopathy,
while an EF measuring above 75% may indicate a heart condition like hypertrophic
cardiomyopathy. The risk factors associated with CVD can be fatal, and even with
emerging medicine and development of new technologies for diagnosis and treatment,
healthcare providers require more information to combat the aggressiveness of CVD.

1.5 Objectives
Understanding the intraventricular function and hemodynamic effect with a
dangerously low EF and high-risk to heart failure could be used as a preventative
measure to the progressiveness of CVD and drastically change the mortality rate. The
specific aim of this project is to investigate the hemodynamics inside the LV and how the
fluid motion is altered by implementing a ventricular assist device to bypass blood flow
from the left ventricle directly into the aorta. Understanding the hemodynamic data
obtained from simulation experiments can provide clinically important metrics such as
pressure gradients, wall shear stresses (WSS), and vortex propagation.19 These assist
devices, or heart pumps, are used when the volume of blood ejected from the ventricle is
not adequate to pump enough blood to the rest of the body due to dilated
cardiomyopathy. Developing computational cardiovascular hemodynamics, by means to
realize a numerical model, could replicate cardiac pathologies and provide insight on the
process. Appropriate models and experimental data are the beginning tools and methods
that can be used for rapid validation of patient-specific computational models in the
future. This could provide virtually unlimited access to cardiovascular dynamics data
12

and hemodynamic features of the system that would be exceedingly diﬃcult or even
impossible to obtain otherwise.
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CHAPTER II
METHODS
2.1 Fluid Dynamics Duplicator
A cardiovascular duplicator was used to replicate the dynamics in the LV, shown
in Figure 6. The experimental apparatus included an electric motor driving a cam which
imposes a prescribed displacement in time of a pneumatic piston/cylinder. This cylinder
was linked directly to a transparent plexiglass box containing a synthetic ventricle model
made of transparent silicon rubber with a wall thickness of 2-3 mm. The transparent
plexiglass allowed for observation of the left ventricle’s contraction over time. The time
dependency imposed by the pneumatic cylinder was replicated by the fluid in the tank in
which the ventricle was immersed. The volume of water being pumped by the piston
caused the ventricle to contract and pump water in from its mitral valve, flush the walls
of the ventricle, and contracted the fluid out through the aorta.

Figure 6

Front and Lateral views of the experimental apparatus.
14

The density of the silicon was almost identical to that of the myocardium (1040
Kg/m3 vs 1060 Kg/m3) and was three times stiﬀer than the biological tissue (E =1.5 MPa
vs max E =0.5 MPa). This difference was compensated for by fabricating the ventricle
thickness to be three times smaller than the myocardium (≤1 cm). The LV was fixed to a
rigid plate at the top of the box where the channels connected to the mitral and aortic
valve perform the function for allowing the inﬂux/outﬂux of the ﬂuid into/from the
ventricle. The LV model was connected to two rigid pipes, both with an inner diameter
of 24 mm, which represent the mitral and aortic channels extended from the rigid plate.
The mitral leaflets were shaped out of silicon sheets, and the main structural difference
was that the leaflets did not have chordae tendineae. They were attached to a ring of rigid
tube then sutured onto a flexible tube made from medical gauze silicon that fit directly
into the mitral channel. The aortic valve was a simple check valve fixed directly to the
opening of the rigid pipe in the aortic position of the LV.
The attached LV was sealed inside the plexiglass box using silicon and the fluid
flow loop was completed by attaching the tubes to the aortic and mitral openings.
Demineralized water was pumped through the LV which then flowed into the double
branched hydraulic circuit representing the circulatory system. Since the working fluid
was deionized water with a viscosity approximately four times smaller than blood, the
cam frequency was four times smaller than that of the biological heart as to operate in
dynamic similarity. The rotation rate was fixed to 15 rpm to reproduce a 60bpm HR, and
the volume displaced by the cam was set to represent a low EF in the LV.
In the branch with the windkessel, a smaller plexiglass box was connected in
series to simulate the vascular capacitance while gate valves regulated the impedance of
15

the systemic circulation. Figure 7 depicts a diagram of the setup as well as the heart
pump used to assist the flow and ejection of the ventricle. The inflow tube of the pump
attaches to the ventricle inside the plexiglass chamber, and the outflow tube directly
brings the flow back into the tank. The fluid loops through the hydraulic circuit then
returns into the ventricle through the duct as a new cardiac cycle begins.

inflow

outflo

Figure 7

(a) Schematic diagram of the experimental setup, with direction of flow. (b)
CAD rendering of the pump with inflow/outflow channels.

The healthiness of the ventricle can be quantified using the EF which quantifies
the ventricle’s pumping function or efficiency. The amplitude of the flow rate evolution
over time correlates to the EF of the ventricle, the higher the amplitude the greater EF of
the LV. The EF, which is the percentage of blood ejected from the ventricle per cycle,
can be defined as:
𝐸𝐹 =

𝐸𝐷𝑉−𝐸𝑆𝑉
𝐸𝐷𝑉

∗ 100

(1)

The difference of the end diastolic volume (EDV) and end systolic volume (ESV)
can also be described as the volume of the cam used which ejected a prescribed volume
of fluid out of the LV. This difference, 𝐸𝐷𝑉 − 𝐸𝑆𝑉, is the amount of blood ejected from
16

the ventricle during one complete cycle, also known as the stroke volume (SV).
Maximum volume in the ventricle is reached during EDV when the myocardium is fully
relaxed just prior to the onset of contraction, while the minimum volume is during ESV
when the myocardium ends its contraction. The details of the structures’ shapes and
geometries, the material properties, and the experimental configurations were chosen and
set as the standard to replicate realistic conditions as close as possible. The ventricle
should have a 2 mm thick wall with a density ρ*=1.04 g/cm3 and Young Modulus E*=
1.5 MPa.
Blood in this case is considered a Newtonian fluid and the ﬂow is incompressible
and viscous. The blood is assumed to be Newtonian as it is known that its non–
Newtonian nature strongly occurs only in vessels of diameter smaller than 15−20 red
blood cell diameters (∼80−100 µm) which is far from the ventricle case.26 The working
fluid within the ventricle, deionized water, has a kinematic viscosity υ= 1.2x10-6 m2/s,
which is about 4 times smaller than that of blood. Therefore, the velocity UM must be
four times smaller than in a real heart to operate in dynamic similarity. This implies that
the cam frequency must also be four times smaller than that of the heart to keep identical
fluid flow and maintain the same Reynolds number. Accordingly, the rotation rate was
ﬁxed to 15 rpm to reproduce a cardiac cycle of 60 beats per minute. External forces such
as pressure fluctuation and viscous stress influence deformation. Pressures for the natural
mitral valve influence the vortex and were determined in previous experiments. With a
reduced EF of 20%, ∆p ≈ 0.24 kPa (1.83 mmHg) represents the approximate value of the
mean transvalvular pressure gradient at the leaflets for the reference case. Normal
hemodynamics parameters in an adult20 were physiologically accurate and within range,
17

therefore these values could be used as parameters for the quantitative data found in
experimental results.
2.2 Ejection Fraction Estimation
Four ventricular volumes under conditions of DCM experiencing a low EF were
calculated. The boundaries of the ventricle were traced in order to find the area within the
myocardium. This would be useful for future experimental runs to confirm the volume
and accurately find the EF. Figure 8 shows the volume estimation of the ventricle using
the depth, D, and length, L, of the ventricular shape. The equation:
4𝐴

𝐷 = 𝜋𝐿

(2)

Can be modified to estimate the volume, V, as:
𝜋

𝑉 = 6 𝐷2 𝐿

Figure 8

(3)

Ventricular volume estimation technique [Wisneky et. Al. Circulation 1981]
18

In this part of the study, cam volume was set to 70 ml. As seen in Figure 9, EDV
and ESV were calculated at each volume of the ventricle using a volume estimation
MATLAB program. It was observed that the EF was indeed far below the normal range
(50-70%), with the highest EF achieved at 35% and the lowest at 19%. There was a
direct correlation between ventricular efficiency and volume. As the volume increased
representing a more severe case of DCM, the EF decreased towards a dangerously low
percentage that would be indicative of heart failure.

Figure 9

EDV and ESV calculated for each of the four sizes of the ventricle analyzed.
The EF (%) was calculated for each volume of the ventricle outlined in red.
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2.3 Left ventricular assist device implementation:
The apparatus was altered slightly to accommodate the implementation of a
continuous flow pump to simulate a Jarvik LVAD hooked up to the ventricle. To
complete this setup, a tube was attached to the apex of the left ventricle and run out of the
closed system and connected to the pump. This presented a potential complication as
attaching a tube to a delicate silicon LV contracting in a system under pressure could lead
to serious problems when running experiments, such as twisting of the tube or collapse or
tearing of the LV itself. The silicon rubber tube used to connect the LV to the pump was
rigid enough to properly draw fluid from the ventricle but also flexible enough that it
would not damage the ventricular walls. Since it was made of silicon, the properties of
the tube were very close to that of the ventricle making it easily attachable with some
flexibility but also being sturdy enough that it was able to withstand many cycles of
running experiments. The same process outlined in the appendix for creating a silicon
ventricle was carried out with the addition of attaching the silicon tube to the apex of the
ventricle.
Pump Specifications
The mock heart pump was made of two parts, the micro pump controller which
hooked to the pump itself allowing the user to set the desired flow rate by adjusting the
frequency. The pump was an RS electronics MG2000 series pump capable of delivering
consistent flow under a wide range of pressures and viscosities. CNC machined
aluminum alloy made up the body while the wetted parts were stainless steel, PEEK,
polyacetal, and PTFE. The controller was an EQi control board able to accept an input
voltage up to 30v DC, while the output voltage was controlled directly by the on-board
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speed control pot or using an external 0-5v input. The pump and controller can be
visualized in Figure 10.
Speed of the pump was maintained with input voltages above 12v as the
controller worked to maintain a constant flow despite back pressure increases. This
provided a flatter flow-pressure curve. The electrical connection was a 2-screw terminal
input and 3 screw terminal output. In this case, there wasn’t an external 0-5v control for
the speed, so the speed control pot located on the board was used. The on-board pot
control did not have stops to protect it from damage, so it was turned continuously using
a small screw driver to increase or decrease the pump velocity.

Figure 10

Heart pump with inflow/outflow tubes and the controller board used to
calibrate flow rate

The pump was calibrated prior to experimental use, and the control pot was turned
to adjust the speed of the pump and achieve the desired flow rates. The pump reached a
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maximum flow rate of 24 ml/s with an intermediate velocity of 17 ml/s and minimum
flow rate of 13 ml/s.
Figure 11 depicts images of the LV compared without and with the pump in the
experimental setup. Notice the particles illuminated inside along with the mitral valve.

Figure 11

(a) LV illuminated with the particles (b) LV with heart pump inserted at the
apex of the ventricle

The tube that connects to the pump can be visualized in Figure (b), taking note that a
portion lies within the ventricular myocardium to simulate a realistic VAD like the
Jarvik.
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2.4 Particle Image Velocimetry
Particle Image Velocimetry (PIV) is a flow visualization/experimental technique
not based on any simulation. The primary components involved in a generalized PIV
setup include, particles to seed the fluid, a laser sheet to illuminate the particles, and a
camera to capture the fluid flow. A diagram including all the primary components used
in PIV analysis can be seen in Figure 12.
Particles must match the properties of the fluid, otherwise it is difficult to track
the flow patterns for accurate PIV measurements. The particles used in this experiment
were pine pollen, spherical in shape and the same density as deionized water. Refractive
index was important when choosing the right particles; the refractive index of the
particles and the fluid differed to allow the laser to reflect sufficient light off the particles
to be scattered to the camera. The particles used, in this case pine pollen, were 50 µm in
diameter; this size was chosen so they could scatter a significant amount of light while
able to follow the fluid motion accurately.
The laser was used to emit a high-power beam and consisted of a cylindrical lens
to expand the beam into a plane and a spherical lens to compress this plane into a very
thin sheet. This sharp laser sheet was crucial to maintain a 2-dimensional plane for
correct PIV analysis, although it was not a 2-D sheet but merely elicited the desired 2-D
characteristics. Correct lenses and laser wavelengths were selected to clearly visualize
and focus on the particles being tracked.
The high-speed camera (Slow Motion Camera Company 1000fps model)
contained a 256 GB built-in memory and a max image resolution of 1280x720 with pixel
size at 6.6 microns. The camera operated at a frame rate of 1000 frames per second and
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captured the flow in 4 second cycles for 10 complete periods. Successive exposed
images were saved in their raw format (Adobe DNG raw output files) to not risk losing
data processed later. A series of images of the contractions were collected for post
processing (PIV) where flow characteristics were computed.

Figure 12

PIV setup showing the major components: the tank seeded with particles, a
laser producing a light sheet, a camera imaging the illuminated particles, and
a PIV system (computer) to analyze the images

Cross correlation was used, where small sub images (interrogation windows) were
cross correlated to derive the probable particle displacement in the interrogation regions.
To ﬁnd the displacements of groups of particles over a short time interval, two
successively recorded images were compared. A small sub-area of the ﬁrst image, called
interrogation areas (IA), was compared with a sub-area at the same location in the second
image using a cross-correlation technique. This resulted in the most probable
displacement vector for that particle pattern. The process was repeated for all
interrogation areas of the image pair resulting in a complete vector diagram of the ﬂow
studied. These vectors were converted into finding the velocity using the time between
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frames and pixel size. Derived vector flow fields found from the particles’ displacement
in the analyzed frames was post processed to find more parameters, such as velocity and
other local flow characteristics.
Advantages to PIV analysis techniques include that it is a non-intrusive method to
measuring an entire 2-D cross section of fluid flow. High-speed processing means large
chunks of data (image pairs) can be analyzed on the computer at any time yielding a good
amount of near continuous information to post process. There of course can be some
drawbacks, for example sometimes particles do not follow fluid motion perfectly, usually
because of differences in density. Experiments using water as the fluid, such as this one,
means it is effortless to find inexpensive particles with the same density, like pine pollen
in this case. It is difficult to measure particles in the z-axis plane which is in line with the
camera, it could potentially interfere with measuring the x-y component. To properly
measure particle motion in all plane directions, the setup would require an additional
camera in order to utilize the method of stereoscopic PIV analysis, which could not be
done simply by a ninety-degree rotation of the image plane. A second camera could
accomplish synchronized imaging of the LV with the existing plane measured.
DNG files were loaded into a batch image editor, xnconvert, that enhanced
images and converted images to a Tiff file. Thresholding and enhancement of images was
limited to prevent noise. Three Matlab files were used for processing images and the data
they contained. The first file was a preprocessing program that loaded the folder with the
original Tiff images and prepared it for PIV analysis. The images were phase averaged
and the average subtracted to get a clean series of filtered Tiff images. Although only
one complete cycle of the heart was needed, 10 loops or contractions were used to get an
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accurate averaging of the images. A mask was created in the second Matlab program, to
where the boundaries of the ventricle and shape were shown against the black
background of the figure plot. With this mask, an entirely black and white image was
obtained, with a complete white outline of the ventricle that contrasts against a black
background. The third and final file utilized the preprocessed images from the first file
and performed the PIV processing. The code was derived from the GUI of PIVlab, a
MATLAB software with a PIV user interface. It was edited to suit the needs of running a
complete contraction of the ventricle and calculated the velocities inside the structure
during each loop.
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CHAPTER III
RESULTS
3.1 Ventricle without an implanted assisting device
A ventricle experiencing DCM with a reduced EF, which is the amount of blood
ejected from the ventricle during one complete cardiac cycle, was studied to understand
the intraventricular flow of a damaged LV. This ventricle was used as a guideline to
distinguish and understand the flow inside a damaged ventricle with an assistive heart
pump in place in the next part of the study. A normal LVEF falls within the range of
50%-70%. The EF of the reference case was set to 20%.
In Figure 13, it was observed that the mitral jet forms an intense vortex that
circulated towards the apex, even when experiencing DCM, and attempted to sweep the
inner myocardium of the ventricle.

Figure 13

PIV analysis depicting velocity vectors and vorticity of the transparent LV
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The arrows are in the plane velocity in Figure 13, and the black line outlining the
ventricle is automatically detected by the code during analysis. The vorticity expresses
the rotation rate of flow, represented by red and blue shaded areas. The vorticity in red
means there is a clockwise rotation, which is the main circulation. The blue areas
represent counter-clockwise rotations, which grow in intensity near the myocardium
where the boundary layer takes place. It can be seen that the large scale ﬂow dynamics
can be reliably captured in the experiments. During the initial part of the cardiac cycle i.e.
the diastole, the jet from the mitral valve passes through the mitral valve leaﬂets which
starts to open. Although the EF was low, and recirculation was weak, vorticity managed
to reach the ventricle’s apex during diastole (refer to the first two frames). The ﬂow over
the two leaﬂets results in the propagation of two vortices into the ventricle, one close to
the left wall and the other near the center. The two vortices are directed towards the apex
of the ventricle, but since in the experiments we reproduce the dynamics of a failing left
ventricle the vortices soon dissipate into small scales and the mitral jet is not able to
penetrate down to the apex and wash out the stagnant ﬂuid.
3.2 Ventricle with an implanted assisting device
The purpose of a heart pump was to promote proper ejection and recirculation
within an unhealthy LV. The effectiveness of an assistive pump was investigated to
determine if adequate function could be improved above what is considered life
threatening (𝐸𝐹 ≤ 35%) and restored to the healthy physiological range (50% ≤ 𝐸𝐹 ≤
70%).18
Fig. 14(a) shows the implemented LV pump turned off, so it experienced zero
flow rate out of the ventricle’s chamber through the tube and the EF is unchanged. Fig.
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14(b)-(d) show the pump running at the minimum and maximum flow rate, as well as an
intermediate flow rate. The min, intermediate, and max flow rates of the pump were 13
ml/s, 17ml/s, and 24 ml/s, respectively. Figure 15(a) is the vorticity results with (a) the
pump switched off experiencing zero flow rate, and (b)-(d) running the experiment with
the pump at min, intermediate, and max flow rate.
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Figure 14

PIV analysis depicting velocity vectors of the transparent LV with the pump
undergoing (a) zero flow rate (switched off), (b) minimum flow rate of 13
ml/s, (c) intermediate flow rate of 17 ml/s, and (d) maximum flow rate of 24
ml/s.
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Figure 15

: PIV analysis depicting vorticity with the velocity vectors with the pump
undergoing (a) zero flow rate (switched off), (b) minimum flow rate of 13
ml/s, (c) intermediate flow rate of 17 ml/s, and (d) maximum flow rate of 24
ml/s.
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Two major observations were seen as a result of this data. Velocity vectors
pointed towards the tube when the pump was active. This altered direction of flow
drastically when the assistive device was functioning. The hemodynamics were also
altered as the pump rate increased. The change in hemodynamics as flow rate increased
was more apparent when studying the vorticity, as an intensified main circulation
attempting to reach the inner myocardium forming the boundary layer was observed. The
presence of the pump (through the plastic tube inserted at the apex) created an obstacle
for the flow and sweeping of the apex was significantly reduced with respect to the case
in previous section without the assist device.
3.3 Modified EF
The results obtained for four different pump flow rates with a low EF were
compared. A heart pump imposes its own EF on the ventricle, which must be considered
and included in the calculation to find the new LV EF with the assistance of the pump.
The EF of the heart pump can be defined in Eq (4).
EFpump =

QT
EDV

(4)

∗ 100

with Q being the volumetric flow rate and T, the time, being a complete cardiac cycle, in
this case, one period is four seconds. With the above defined EF equations, a new EF*
with the assistance of the CF pump was calculated combining the two, shown in Eq (5).
𝐸𝐹 ∗ = EF + EFpump =

(EDV−ESV)+ QT
EDV

∗ 100

These equations determine if healthy hemodynamics and EF in the normal range were
restored.
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(5)

Table 1

Qpump

0 ml/s

13 ml/s

17 ml/s

24 ml/s

EF

17.78

17.78

17.78

17.78

EFpump

0

23.11

30.22

42.67

EF*

17.78

40.89

48.00

60.45

Ejection Fraction (%) Estimates for various pump flow rates.

The original fraction of ejected fluid prior to the pump functioning, EF, remained
unchanged throughout all cases in the loop. Only the flow rate and EFpump change, which
makes EF* different in each case. The results of the ejection fraction calculations are
presented in Table 1. As predicted, the increase in pump flow rate directly correlated to an
improvement in the EF toward the normal physiological range. While this shows promising
outcomes for LVAD therapy, in Figure 13 the vortex created from the mitral jet showed
difficulty in reaching the inner walls of the LV down to the apex. The mitral jet points
vertically downward, thus inducing counterclockwise vorticity to its right region and
weakening the overall circulation. The weak, enlarged ventricle caused aberrant flows and
even valve leakage. While the valve was able to close, the leaflets did not properly seal
which could create some backflow and mitral insufficiency. At the site of the mitral valve
leaflets, the valve continues to deform and retract slightly toward the mitral channel,
inducing a local backward velocity that, in spite of this deformation, does not produce valve
leakage. Scientists have described this phenomenon as a ‘false regurgitation’. Despite the
aid of the pump and the correlation between increasing flow rate and improving EF, proper
fluid dynamics in the LV was not reached. This can be visualized in the above figures, 1333

15, where in Figure 13, there is a clearly powerful mitral jet. This intense rush of fluid into
the LV that sweeps the myocardium was not observed in the cases with the heart pump in
place and functioning. Strong probably cause is that due to the presence of the pump it
obstructs the intraventricular dynamics somehow, and the continual flow inhibits this
mitral jet and formation of necessary vorticity not seen in Figure 15. This could lead to
flow stagnation and insufficient unloading of the LV, causing the pump to fail as well as
improper circulation through the systemic loop. Improper circulation from the heart pump
can cause clots which can further damage the LV, and if the clots begin to break off into
the blood system and reach the brain, this can cause a stroke. Studies on the physiological
effects of LVADs show that CF-LVADs have led to an increase in degradation of the aortic
wall tissue, which could also mean degradation of the myocardium of the LV. Thrombosis
and higher degrees of hemolysis have also been seen in CF-LVADs, and while it is still
unclear the clinical significance of these effects, there are important physiological factors
to be considered with LVAD therapy.11
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CHAPTER IV
DISCUSSION

Heart failure, specifically due to dilated cardiomyopathy, often begins in the left
ventricle. This typically leads to a decreased EF, further myocardial disease and possible
infection, and aberrant blood flows inside the ventricle. LVADs assist the heart and
unload some of the stress on the LV when it is unable to function properly. However, it
is unclear how effective these pumps are at restoring healthy fluid flow and physiological
EF. Studies also show LVADs have a relatively short lifespan so continued long-term
use may be unsatisfactory but also short-lived. Observation of the continuous pump flow
and its effectiveness to provide unloading on the ventricle yielding the EF to increase
may improve understanding of LVADs and their potential drawbacks, which could lead
to more promising clinical and therapeutic techniques for DCM.
Experiments were run on a transparent silicon LV model implemented in a fluid
flow loop to represent systemic circulation. PIV analysis of the fluid flow was performed
computationally, and the effect the reduced EF had on the ventricle could be observed,
and the results with the addition of the pump. In healthy cases, the early phase of the Ewave is where the mitral jet starts until early systole where a full ventricle and increased
pressure leads to ejection through the aortic valve. The A-wave typically reinforces the
vortex originally generated by the E-wave mitral jet; however, in the case of an impaired
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LV, a weaker recirculation is introduced and expelled during systole.18 This new
recirculation can be observed in the reference case of the LV experiencing DCM,
beginning between the posterior mitral leaflet and inner wall of the myocardium.
Although unloading of the LV occurs with the introduction of an assistive pump like an
LVAD, proper fluid dynamics within the normal physiological range was not achieved,
therein lies remaining problems only partially solved using a LV heart pump. Healthy
ventricular dynamics could not be achieved due to unsustainable EF in the physiological
range. While under maximum pump flow rate, the new EF was calculated around 60%,
which is an acceptable EF. Analysis of the flow shows unsatisfactory flow at the apex of
the ventricle, near the pump attachment site. Reasons for this could be that the portion of
the pump inserted into the LV causes an obstruction, which limits the flow paths and
desired circulation along the wall. High risks for clots due to LVADs is one of the
number one complication with this medical device, and restriction of flow where the
pump meets the myocardium is an optimal site for flow stagnation, clotting, and therefore
improper fluid dynamics. Some obstacles are unable to be overcome to achieve healthy,
physiological flow, and while introducing a device to restore function to the LV,
introducing a foreign device into the body carries its own set of drawbacks. The
outcomes of this study should not be debunked since it raises concern over the true
advantages and disadvantages of invasive medical therapy such as ventricular assist
devices.
4.1 Study Limitations and Future Studies
As an in vitro study, the model is merely representative of what occurs in a LV in
vivo. While parameters were set to match as closely as possibly a biological ventricle,
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deviations from LV and valve leaflet properties as well as in vivo flow are possibilities in
the experimental model. Despite efforts to mimic a natural ventricle, there remain
relevant diﬀerences between the present model for the left ventricle and the intended real
human heart that should be considered when applying the results to clinical cases. An
important diﬀerence is the inner structure of the endocardium that is characterized by
irregular grooves (trabeculae) and far from the smooth surface modelled here. Another
key difference is the lack of presence of the chordae tendineae, ﬂexible and inextensible
’ﬁlaments’, that link the leaﬂets tips to the myocardium through the papillary muscles;
these structures tense during the systole and prevent the leaﬂets from everting or folding
back into the atrium. No tensile or stress test was performed on the silicon rubber to
quantifiably measure its elasticity or stretching/relaxing capability. Since the density is
non-uniform in the flow domain, pressure was only able to be computed numerically
using slow iterative methods. Complex algorithms and procedures have restricted study
of multiphase flow, and computational dynamics should be produced to verify
experimental data. To understand and simulate dispersed multiphase ﬂows, development
of relatively computationally inexpensive alternative methods that still account for the
various active physical mechanisms in the ﬂow is needed. The characteristics and
function of the model ventricle were confirmed by a cardiothoracic surgeon and
reproduced to match the desired attributes. Production of ventricles that were identical
was nearly impossible since the fabrication was done in lab by heating the rubber onto a
shape that represented the mold of a ventricle. The difference in stiffness between the
silicon and biological tissue was compensated by making the ventricular wall thickness
about three times smaller than that of the myocardium. This is still far from realistic
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conditions when considering that the myocardium is anisotropic, because of the ﬁber
orientation, and hyperelastic. Even using the same steps, minor blemishes or impurities
could have been introduced into the silicon ventricle. Additionally, hemodynamic effects
such as clotting could not be considered, which have been shown in other studies to be a
major drawback on CF-LVAD use due to the likelihood of clot formation and
thrombosis.14 Current in vitro studies only capture the isolated effects of geometric
changes on fluctuations in the valve models, and this study could not consider patient to
patient cases or any genetic or physiologic variations. Echocardiographic PIV (E-PIV)
has been performed in many other studies to understand the fluid flow inside the left
ventricle.28 Potential follow up studies could compare the techniques and results
associated between in vivo E-PIV of the LV and in vitro PIV analysis on model LVs.
Future studies should utilize more prior testing of the system and LV characteristic
affects to different stresses and loads for further attempts to mimic the human LV, both
healthy and diseased.
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CHAPTER V
CONCLUSIONS
In conclusion, the current study analyzed the flow in a model LV with parameters
to simulate a reduced EF due to myocardial disease. With an implemented CF pump,
fluid mechanics were altered due to a decreased EF in the diseased ventricle, and the
assistive pump effect on the fluid flow were studied. Assistance from the pump
contributed to unloading on the ventricle and yielded the EF to increase towards a healthy
physiological range; however, proper recirculation at the apex and blood sweeping of the
myocardium did not show much improvement under varying velocities of the CF pump.
While LVADs provided the needed ejection of blood from the LV to properly function in
a healthier state, long term use did not reverse the effect of an enlarged, weakened LV
due to diseased myocardium and produce the necessary ventricular hemodynamics.
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APPENDIX A
SILICON VENTRICLE FABRICATON
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Construction of transparent silicon LV
1)
Prepare a 10:1 ml ratio of Prochima Cristal Rubber transparent silicon gel with Ptcure catalyst, respectively, mixing well to reduce air bubbles.
2)
Ensure the plexiglass shape of the left ventricle used to make the mold is
thoroughly clean and dry.
3)
Using a small brush, paint an even layer of the mixture on the shape keeping
uniform brush stroke and silicon amount.
4)
Secure base of ventricle shape to tile with excess silicon gel to make base
attachment.
5)
Dry the shape using a thermal gun (Steinel HG 2310 LCD) at a high temperature
of at least 250 degrees Celsius until set (approximately 10 minutes).
6)
Rest and cool the shape by fanning and letting sit for 5-10 minutes until
completely dry.
7)
Repeat the process adding more layers the silicon mixture until 7 layers thick,
adding excess to the aortic and mitral channels and the junction between them.
8)
Detach shape from the tile after the silicon is completely set and dry using a
scalpel to cut around the base and edge of the valve openings.
9)
Add an excessive amount of glycerol inside between the plexiglass shape and
ventricle mold using a syringe and tube
10) Slip off the shape carefully once plenty of glycerol has been used to lubricate the
space between the shape and the silicon ventricle.
11) Wash thoroughly but gently with water and ensure there are no holes or leaks.
12) Ensure all glycerol has been rinsed from the shape and quickly dry the silicon
ventricle once more before letting it air dry.

IMPORTANT: The small amount of catalyst in the mixture is what allows the silicon gel
to set properly. If the ratio is not exact or uniform throughout the process, the mold will
not dry and polymerize properly. It is crucial to ensure a layer of silicon is completely
dry before adding another layer.
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Ventricle for heart pump
1. Repeat steps 1-7 above for making a transparent silicon left ventricle.
2. Take tube after the final layer of silicon is dry and place one end in the desired
position on the apex of the ventricle.
3. Secure tube to the apex of ventricle using silicon all around the end of the tube at
the conjoining point and dry thoroughly*
4. Repeat adding silicon at the junction between tube and ventricle drying at high
temperatures (about 290-300 degrees Celsius).
*Be careful not to let any silicon gel drip down the sides of the ventricle
wall

5.

Continue with the final steps of detaching the ventricle from the shape once the
tube is securely attached, taking extra care now not to tear the ventricle with the
tube attached.

6. Rinse thoroughly once the ventricle with the tube is detached ensuring there are
no holes in and dry.
7. Cut a hole very carefully at the apex of the ventricle from the inside where the
tube attaches so the chamber of the ventricle and the tube are connected.
- This is where the pump will draw water from the ventricle directly into the
system.

47

